Original Article
ABO-Incompatible Heart Transplantation in Infants
N Engl J Med 2001; 344:793-800March 15, 2001
- Abstract
Background
Transplantation of hearts from ABO-incompatible donors is contraindicated because of the risk of hyperacute rejection mediated by preformed antibodies in the recipient to blood-group antigens of the donor. This contraindication may not apply to newborn infants, who do not yet produce antibodies to T-cell–independent antigens, including the major blood-group antigens.
Methods
We studied 10 infants, 4 hours to 14 months old (median, 2 months), who had congenital heart disease or cardiomyopathy and who received heart transplants from donors of incompatible blood type between 1996 and 2000. Serum isohemagglutinin titers were measured before and after transplantation. Plasma exchange was performed during cardiopulmonary bypass; no other procedures for the removal of antibodies were used. Standard immunosuppressive therapy was given, and rejection was monitored by means of endomyocardial biopsy. The results were compared with those in 10 infants who received heart transplants from ABO-compatible donors.
Results
The overall survival rate among the 10 recipients with ABO-incompatible donors was 80 percent, with 2 early deaths due to causes presumed to be unrelated to ABO incompatibility. The duration of follow-up ranged from 11 months to 4.6 years. Two infants had serum antibodies to antigens of the donor's blood group before transplantation. No hyperacute rejection occurred; mild humoral rejection was noted at autopsy in one of the infants with antibodies. No morbidity attributable to ABO incompatibility has been observed. Despite the eventual development of antibodies to antigens of the donor's blood group in two infants, no damage to the graft has occurred. Because of the use of ABO-incompatible donors, the mortality rate among infants on the waiting list declined from 58 percent to 7 percent.
Conclusions
ABO-incompatible heart transplantation can be performed safely during infancy before the onset of isohemagglutinin production; this technique thus contributes to a marked reduction in mortality among infants on the waiting list.
Media in This Article
Figure 1
Serum Antibody Development in Surviving Infants with Grafts from ABO-Incompatible Donors Transplanted before the Onset of Isohemagglutinin Production.Table 1
Compatible and Incompatible Combinations of Blood Type for Potential Organ Donors and Recipients.Article Activity
- Article
Solid-organ transplantation between donors and recipients with incompatible blood groups is usually contraindicated because of the high risk of hyperacute rejection. Such rejection occurs when preexisting serum anti-A or anti-B antibodies (natural isohemagglutinins) in the recipient bind to their respective blood-group antigens on vascular endothelial cells of the donor organ, resulting in the activation of the complement cascade and rapid thrombosis in the vasculature of the graft.1-3 Although undertaken occasionally in kidney and liver transplantation,2,4-12 ABO-incompatible transplantation of hearts has been reported rarely — only as an inadvertent occurrence and often with a lethal outcome.13
Newborn infants do not produce isohemagglutinins, and serum anti-A or anti-B antibody titers usually remain low until the age of 12 to 14 months.14 Furthermore, the complement system is not fully competent in young infants.15 Thus, the primary factors that would initiate hyperacute rejection are absent during early infancy.
Infants with lethal cardiac disease often die before transplantation because of the shortage of donor hearts,16,17 with patients in blood group O encountering disproportionate competition for organs (Table 1Table 1
Compatible and Incompatible Combinations of Blood Type for Potential Organ Donors and Recipients.). Furthermore, when organs become available from donors who have the less common B and AB blood types, there may be no recipients of appropriate size with compatible blood types awaiting transplantation, so these organs go unused.We reasoned that ABO-incompatible transplantation would be safe during early infancy because of the recipients' relative immunologic immaturity. We therefore performed cardiac transplantation in 10 infants using hearts from donors of incompatible blood groups.
Methods
Patients
Since January 1996, parents of fetuses and infants referred for cardiac transplantation at the Hospital for Sick Children in Toronto have been offered the heart from the first available donor of compatible size, regardless of blood type. Except for two older infants, only infants with no serum antibodies to blood-group antigens were considered. The protocol was approved by the institutional ethics committee, and all parents gave written informed consent. We compared the results in the 10 infants who received hearts from ABO-incompatible donors between January 1996 and January 2000 with those of 10 infants who received hearts from ABO-compatible donors during the same period.
Blood Group and Antibody Status
The blood type of recipients was determined by means of standard blood-bank procedures for all infants except those placed on the waiting list while still in utero, whose blood type was determined at birth. The blood type of donors was provided by the referring organ-procurement agency.
Serum from all infants except those placed on the waiting list antenatally was tested for the presence of anti-A and anti-B antibodies by means of standard agglutination tests with erythrocytes from blood whose type was known (reverse blood typing); 0.1 ml of the patient's serum diluted with saline in a ratio ranging from 1:1 to 1:256 was mixed with 0.1 ml of a suspension of 3 to 5 percent erythrocytes of blood groups A and B (Ortho Diagnostics), incubated at room temperature for 1 hour, and centrifuged at low speed for 60 seconds. Erythrocytes from type O blood were used as controls in testing for the presence of other alloantibodies; saline was used as a negative control. If antibodies were detected, the isotype (IgG or IgM) was not determined.
Testing for serum antibodies was repeated periodically, and it was performed immediately when a potential donor was identified. The tests were also conducted during the operation before the release of the aortic cross-clamp and every six hours for four days after transplantation. In recipients without antibody production before transplantation, subsequent testing was repeated daily for two weeks, weekly for two months, then monthly. In the older recipients, testing was repeated more frequently.
Preparations of Blood Products for Cardiopulmonary Bypass
For recipients with type O blood, the bypass circuit was primed with plasma from blood of either the donor's blood type or type AB, which therefore carried no antibodies to the donor's blood group. In the one recipient with type A blood who received a heart from a donor with type B blood, plasma from type AB blood was given to avoid introducing antibodies directed against the blood types of both the donor and the recipient. All cellular products (except platelets) administered intraoperatively and postoperatively were from group O blood (or the recipient's blood group) and therefore expressed no exogenous A or B antigens. All plasma products were from group AB blood (or the donor's blood type when the recipient had blood group O) and therefore carried few or no exogenous anti-A or anti-B antibodies (Table 2Table 2
Blood Groups Required for Blood Products Administered during ABO-Incompatible Heart Transplantation.).Although platelets express low levels of A or B antigens, platelets from group O blood were not used with recipients with blood type O, because substantial quantities of anti-A and anti-B antibodies would be expected to appear in preparations of platelets from group O blood. These antibodies could be more detrimental in initiating hyperacute rejection of ABO-incompatible grafts than additional A or B blood-group antigens expressed in preparations of platelets from blood of the donor's blood group. Thus, platelets from group AB were used (or from blood of the donor's blood type, in the case of recipients with type O blood). Because sufficient platelets from type AB blood were not available, saline-washed platelets from type A blood were also given, with no apparent adverse effect.
Intraoperative Procedures
Orthotopic heart transplantation was performed by standard surgical techniques. During cardiopulmonary bypass, approximately three times the total body volume of plasma was exchanged. Blood equal in volume to the estimated circulating blood volume was removed from the infant during the initiation of bypass through the line for venous return to the bypass circuit and was replaced with an equal volume of blood from a blood bank and plasma from type AB blood. The infant's blood was separated into plasma and red-cell fractions by the hospital's blood bank or by means of a commercial blood-salvage system (Sequestra 1000, Medtronic). The plasma was discarded and the red-cell fraction was returned through the bypass circuit. This procedure was repeated up to three times during bypass to reduce to undetectable levels the concentrations of circulating antibodies to blood-group antigens; the reduction was confirmed before the aortic cross-clamp was released.
Immunosuppressive Treatment
All infants received 30 mg of methylprednisolone per kilogram of body weight intravenously during the operation, and they received induction immunosuppression with the use of rabbit polyclonal antithymocyte antibody immediately after the operation and until renal function normalized (median duration, 6 days [range, 3 to 14]; dose, 0.15 ml per kilogram per day intravenously, adjusted to yield a lymphocyte count of 200 to 400 per cubic millimeter). Primary immunosuppression of the first two recipients of hearts from ABO-incompatible donors and all recipients of hearts from ABO-compatible donors consisted of cyclosporine (Neoral, Novartis Canada; initial oral dose, 8 to 10 mg per kilogram per day; target plasma concentration, 250 to 325 ng per milliliter, according to enzyme-multiplied immunoassay), azathioprine (2 mg per kilogram per day orally), and prednisone (3 mg per kilogram per day orally, decreasing to 0.25 mg per kilogram per day during the first 10 days after transplantation). Subsequent recipients of hearts from ABO-incompatible donors received primary immunosuppression with newly available drugs that may have a greater effect than the combination of cyclosporine and azathioprine on B-lymphocytes and thus on antibody production.18,19 These patients were given tacrolimus (Prograf, Fujisawa Canada; initial oral dose, 0.1 to 0.3 mg per kilogram per day; target plasma concentration, 8 to 12 ng per milliliter) with mycophenolate mofetil (Cellcept, Hoffmann–LaRoche Canada; initial oral dose, 20 to 40 mg per kilogram per day) and prednisone (in the doses described above).
In all infants, the doses of adjunct immunosuppressive medications (prednisone and either azathioprine or mycophenolate mofetil) were gradually decreased, and the drugs were discontinued if no rejection occurred. The doses of calcineurin-inhibitor drugs were reduced over time (target plasma concentration one year after transplantation, 150 to 200 ng per milliliter for cyclosporine and 4 to 6 ng per milliliter for tacrolimus), so that total immunosuppression was maintained at the lowest level required to prevent rejection. Infants who received cyclosporine-based therapy and who had recurrent rejection or unacceptable side effects or in whom it was impossible to reduce the drugs to low doses or discontinue glucocorticoid therapy were switched to tacrolimus-based maintenance therapy. Patients 1 and 7 were switched from tacrolimus to cyclosporine because of gastrointestinal disturbance and anemia (in one patient each). Acute cellular rejection was treated with methylprednisolone (given in intravenous doses of 10 to 15 mg per kilogram per day for three days). If humoral rejection had occurred, plasmapheresis would have been performed, combined if necessary with the administration of cyclophosphamide (1 to 2 mg per kilogram per day).
Surveillance for Rejection
All infants underwent endomyocardial biopsy for the detection of acute cellular and humoral rejection at intervals of approximately three to four weeks, or earlier if possible rejection was indicated by changes in clinical status (fever, hypotension, lethargy, irritability) or by the results of electrocardiographic studies (decreased QRS voltages or new rhythm abnormalities) or echocardiographic studies (decreased ejection fraction or increased wall thickness). The biopsy specimens were stained with hematoxylin and eosin and were examined by pathologists with expertise in cardiac-transplant biopsies, who assessed them according to the criteria of the International Society for Heart and Lung Transplantation.20 Histopathological features of antibody-mediated rejection included interstitial edema or hemorrhage and swelling of the endothelial cells. Immunohistochemical analysis was performed with the use of fluorescent tagged antibodies to IgG, IgM, IgA, C3, and fibrinogen. Coronary angiography was performed within six months after transplantation, then annually, to identify chronic rejection (accelerated coronary artery disease in the graft), a process that may be associated with antibody-mediated damage.21
Results
The median age at the time of transplantation in the recipients of grafts from ABO-incompatible donors (Patients 1 through 10) was two months (Table 3Table 3
Characteristics of Patients Who Received Heart Transplants from ABO-Incompatible or ABO-Compatible Donors.). A retransplantation (with a graft from an ABO-compatible donor) was performed urgently in Patient 2 after a traumatic injury to the initial graft during transport. Data on 10 recipients of grafts from ABO-compatible donors (Patients 11 through 20) who underwent transplantation at a median age of 5.5 months were used for comparison (Table 3).Serum Antibody Titers before Transplantation
Serum anti-A or anti-B antibodies were detected before transplantation in four recipients of hearts from ABO-incompatible donors (Table 4Table 4
Pretransplantation Serum Isohemagglutinin Titers in Recipients of Heart Transplants from ABO-Incompatible Donors.). Patients 2 and 10 had low titers of isohemagglutinins (1:2 or lower), presumably maternal in origin, given the infants' ages (six months or younger). Patients 4 and 9 had serum antibody titers consistent with normal isohemagglutinin production for their age (14 months).Mortality
Patients 3 and 4 died of causes that were presumed to be unrelated to ABO incompatibility. In Patient 3 (donor's blood type, A; recipient's blood type, O), progressive cardiac hypertrophy developed two weeks after transplantation, and the patient died on day 29. Post-transplantation endomyocardial biopsy and postmortem examination of the transplanted heart revealed no cellular or humoral rejection. No serum anti-A or anti-B antibodies were detected, and there was no deposition of immunoglobulin or complement within the graft. Possible factors contributing to the patient's lethal cardiac hypertrophy were the use of multiple inotropic drugs in high doses22 and neonatal myocardial sensitivity to glucocorticoids23 or tacrolimus24 (which is unlikely at the low doses that were administered).
Patient 4 (donor's blood type, B; recipient's blood type, O), who had detectable serum anti-B antibodies before transplantation that were eliminated during transplantation, died of aspiration pneumonia on day 24 after transplantation. Serum anti-B antibodies were detected the day before death (titer, 1:4), but graft function was normal on echocardiography; a biopsy revealed mild cellular rejection and no humoral rejection. Postmortem examination demonstrated mild cellular and humoral rejection — specifically, edema and vasculitis, with deposition within the graft of immunoglobulin and fibrinogen but not complement. The importance of these findings relative to the clinical outcome is unclear.
Rejection and Modulation of Immunosuppression
No infant had hyperacute rejection. In the recipients with ABO-incompatible donors, acute cellular rejection occurred infrequently: no infant had more than one episode, and the episodes that did occur resolved easily with short-term, high-dose glucocorticoid therapy (Table 5Table 5
Immunosuppressive Therapy and Rejection Patterns in Recipients of Heart Transplants from ABO-Incompatible and ABO-Compatible Donors.). Among the recipients with ABO-compatible donors, there was a slightly higher incidence of rejection episodes overall (Table 5), perhaps because they were not given the combination of tacrolimus and mycophenolate mofetil used for immunosuppression in most recipients with ABO-incompatible donors or because they were older at the time of transplantation (median age, 5.5 vs. 2 months).25 There were no findings consistent with humoral rejection in the recipients with ABO-incompatible donors, except for the autopsy findings, described above, in Patient 4. Chronic rejection (coronary vasculopathy in the graft), as diagnosed by coronary angiography, has not occurred as of this writing in any recipient with an ABO-incompatible donor.Adjunct immunosuppressive therapy has been discontinued in most recipients with ABO-incompatible donors. Five of the eight surviving patients now receive calcineurin-inhibitor monotherapy, and weaning from additional immunosuppressive therapy continues in two patients who underwent transplantation recently. Because of preexisting serum isohemagglutinins at the time of transplantation, Patient 9 has continued to receive low-dose tacrolimus and mycophenolate mofetil.
Morbidity
The recipients with ABO-incompatible donors have had no more chronic problems after transplantation than the recipients with ABO-compatible donors, and increased immunosuppression has not been necessary to prevent or treat rejection. Specifically, no cases of post-transplantation lymphoproliferative disease, severe opportunistic infections, or diabetes mellitus have developed in recipients with ABO-incompatible donors. The frequency of anemia, leukopenia, hypertension, renal dysfunction, serum lipid abnormalities, and feeding difficulties has been similar in the two groups.
Development of Isohemagglutinins after Transplantation
Of the seven surviving recipients with ABO-incompatible donors who still have their original grafts, six were not producing isohemagglutinins before transplantation. According to the most recent follow-up data, production of antibodies to the A or B blood-group antigens in the ABO-incompatible graft has been detected in only two infants (Patients 1 and 6); in these cases, the onset of antibody production was delayed, and titers have remained low (Figure 1Figure 1
Serum Antibody Development in Surviving Infants with Grafts from ABO-Incompatible Donors Transplanted before the Onset of Isohemagglutinin Production.). Despite the production of antibody to the antigens in these grafts, repeated biopsies revealed no evidence of humoral rejection or deposition of immunoglobulin, fibrinogen, or complement within the graft.In contrast, the production of antibodies to the A or B blood-group antigens not expressed in either donor or recipient (for example, production of anti-B antibody in a recipient with blood type O and a graft from a donor with blood type A) has proceeded in a fashion similar to that in the recipients with ABO-compatible donors, suggesting that deficient production of antibody to the antigens in the ABO-incompatible graft is not due to immunosuppression therapy.
Before transplantation, both of the older infants we studied had serum antibodies to the antigens in the ABO-incompatible graft. In Patient 4 (donor's blood type, B; recipient's blood type, O), serum anti-B antibodies reaccumulated within three weeks after transplantation, although the titer remained low at death (1:4), whereas antibody to nonexpressed blood-group A antigen had reaccumulated to a titer of 1:64. Patient 9 (donor's blood type, A; recipient's blood type, O), who had serum anti-A and anti-B antibody titers of 1:128 and 1:16, respectively, before transplantation, had not had a reaccumulation of antibody to the blood-group A antigen in the ABO-incompatible graft 17 months after transplantation, despite having a reaccumulation of antibody to nonexpressed blood-group B antigen 2 months after transplantation.
Effect on Waiting-List Mortality
Before the initiation of this protocol, there were 7 deaths among 12 infants (58 percent) younger than six months old who had been placed on the waiting list for transplants since 1990, with only 2 infants receiving transplants and 3 infants receiving (unsuccessful) surgical palliation. Between January 1996, when our study began, and October 2000, 29 infants younger than six months old were listed as potential recipients of organs from a donor of any blood group, of whom 2 (7 percent) died after waiting six and nine weeks, respectively. Twenty-two infants received transplants (9 from ABO-incompatible donors and 13 from ABO-compatible donors), 3 were treated with other surgery, and 2 were removed from the list after two days of waiting (1 had a lethal genetic syndrome and 1 had an intracerebral hemorrhage).
Discussion
Heart transplantation is a successful therapy for infants with potentially lethal cardiac disease, and results are improving steadily; five-year survival rates are approaching 80 percent in centers with extensive experience.25,26 However, efficient allocation of the rarely available organs is hampered by the presumed need for a recipient who has a blood type that is compatible with that of the donor.
Some aspects of antibody production are not yet developed in infants. In particular, stimulation by T-cell–independent polysaccharide antigens, such as the capsular components of bacteria (e.g., pneumococci), does not elicit a serum antibody response early in life.27,28 Similarly, the production of antibodies to the carbohydrate blood-group antigens begins at the age of six to eight months, in infants of susceptible genotypes, as a cross-reactive immune response after the colonization of the gut with polysaccharide-bearing Escherichia coli. 14,29
Blood-group antigens and isohemagglutinins that develop in persons who lack antigen expression are a major immunologic barrier to organ transplantation.1-3 Nonetheless, the scarcity of donors has spurred efforts to use ABO-incompatible organs, with some success in kidney2,4-10 and liver1,11,12,30 transplantation. The simple removal of antibodies by techniques such as plasmapheresis,4,6,12 immunoadsorption,5,31 or administration of competitive soluble carbohydrate antigen32 is sometimes successful, but reaccumulation of antibodies usually occurs.
In cardiac transplantation, the particularly devastating effects of antibody-mediated rejection, both hyperacute and delayed, have dictated the avoidance of situations in which antibody-mediated rejection may occur. Thus, although HLA compatibility is not the principal determinant of outcome in cardiac transplantation, sensitized patients who have antibodies to the donor's HLA antigens before transplantation are at high risk for graft loss due to humoral rejection.33 Similar considerations have prevented the intentional use of organs from ABO-incompatible donors. In an international survey,13 Cooper found only eight cases of ABO-incompatible heart transplantation, all in adults and all occurring inadvertently because of errors in determining the blood type of the donor. Despite urgent removal of antibodies or retransplantation, only two patients survived.
In this study, we found that heart transplantation between donors and recipients of incompatible blood groups can be performed safely during early infancy. In the absence of preformed antibodies against blood-group antigens, hyperacute rejection did not occur, in keeping with predictions based on experimental evidence in animals and limited clinical experience with the transplantation of other organs. Other than plasma exchange during cardiopulmonary bypass, invasive preparatory procedures to remove antibodies were not required, nor was splenectomy performed to diminish antibody production.
For patients placed on the waiting list antenatally, fetal blood typing was unnecessary. After transplantation, there was no rapid production of antibodies to the incompatible blood-group antigens, in contrast to the clinical course in most adult patients in whom ABO-incompatible transplantation has been attempted. This lack of antibody production is probably due to the patients' immature immune responsiveness to stimulation by T-cell–independent antigens. Thus, in infants who underwent transplantation before the initial development of isohemagglutinins, the clinical course was similar to that of infant recipients with ABO-compatible donors.
Antibodies to the blood-group antigens in the ABO-incompatible graft have thus far developed in only two infants who underwent transplantation before antibody production had begun, and no graft damage has become apparent on histologic examination. Early experience suggested that if ABO-incompatible transplantation could be performed in persons or animals with minimal serum titers of preformed antibodies, graft damage would be avoided when antibodies reaccumulated — a process called accommodation.4-6,32,34-36
Patients 4 and 9 represent a different phase of immunologic maturation. Isohemagglutinin production was under way in these older infants, with relatively high serum antibody titers, which predict a high risk of hyperacute rejection. Nonetheless, hyperacute rejection was avoided with the use of intraoperative plasma exchange as the sole method for the removal of antibodies.
The absence of antibody production or its delay beyond the time expected because of early immunosuppression may be evidence of partial B-cell tolerance induced by exposure to donor antigens during the maturation of the immune system.37-39 This is particularly obvious in Patients 6 and 9 (both recipients with type O blood whose donors had type A blood), who have had increasing production of anti-B antibody but abnormally low production of anti-A antibody.
The generally good results in this series reflect the fundamental immunologic malleability of young infants. Thus, caution must be exercised to avoid excessive immunosuppression in such infants solely because of ABO incompatibility.
It should be noted that these infants were desperately ill at the time of transplantation, most with severe cardiac malformations. Their highest risk of mortality derived from the insufficient availability of ABO-compatible donors. The maximal age at which this protocol may be used safely remains to be determined, but the appropriate population could include all infants in whom serum isohemagglutinins have not yet developed.
We are indebted to the clinical heart transplant team and the cardiovascular perfusionists for their expert assistance in the care of these patients; to the technical staff of the Hospital for Sick Children blood bank; and to Elmer Cruz for assistance with the manuscript.
Source Information
From the Division of Cardiology, Department of Paediatrics (L.J.W., S.M.P.-B., A.I.D., K.J.L., L.N.B.) and the Division of Cardiovascular Surgery, Department of Surgery (J.G.C.), Hospital for Sick Children and University of Toronto, Toronto; the Division of Nephrology, Department of Medicine, Toronto General Hospital and University of Toronto, Toronto (C.J.C.); and the Department of Surgery, University of Alberta Hospitals, Edmonton, Canada (I.M.R.).
Address reprint requests to Dr. West at the Hospital for Sick Children, 555 University Ave., Toronto, ON M5G 1X8, Canada, or at lwest@sickkids.on.ca.
- References
References
1
Starzl TE ,Ishikawa M ,Putnam CW , et al. Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc 1974;6:Suppl 1:129-139
Web of Science | Medline2
Paul LC ,Baldwin WM III . Humoral rejection mechanisms and ABO incompatibility in renal transplantation. Transplant Proc 1987;19:4463-4467
Web of Science | Medline3
Stock P ,Sutherland DE ,Fryd DS , et al. Detrimental effect of ABO mismatching in renal transplantation. Transplant Proc 1987;19:711-712
Web of Science | Medline4
Slapak M ,Naik RB ,Lee HA . Renal transplant in a patient with major donor-recipient blood group incompatibility: reversal of acute rejection by the use of modified plasmapheresis. Transplantation 1981;31:4-7
CrossRef | Web of Science | Medline5
Bannett AD ,Bensinger WI ,Raja R ,Baquero A ,McAlack RF . Immunoadsorption and renal transplant in two patients with a major ABO incompatibility. Transplantation 1987;43:909-911
Web of Science | Medline6
Alexandre GPJ ,Squifflet JP ,De Bruyere M , et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987;19:4538-4542
Web of Science | Medline7
Sutherland DE ,Fryd DS ,So SK , et al. Long-term effect of splenectomy versus no splenectomy in renal transplant patients: reanalysis of a randomized prospective study. Transplantation 1984;38:619-624
CrossRef | Web of Science | Medline8
Takahashi K ,Yagisawa T ,Sonda K , et al. ABO-incompatible kidney transplantation in a single-center trial. Transplant Proc 1993;25:271-273
Web of Science | Medline9
Tanabe K ,Takahashi K ,Sonda K , et al. ABO-incompatible living kidney donor transplantation: results and immunological aspects. Transplant Proc 1995;27:1020-1023
Web of Science | Medline10
Osorio AV ,Sullivan EK ,Alexander SR ,Bryan CF ,Shield CF ,Warady BA . ABO-mismatched renal transplantation in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) and the Midwest Organ Bank (MOB). Pediatr Transplant 1998;2:26-29
Medline11
Gugenheim J ,Samuel D ,Reynes M ,Bismuth H . Liver transplantation across ABO blood group barriers. Lancet 1990;336:519-523
CrossRef | Web of Science | Medline12
Eid A ,Zamir G ,Yaron I , et al. Liver transplantation across the ABO barrier: the role of plasmapheresis. Transplant Proc 1998;30:701-703
CrossRef | Web of Science | Medline13
Cooper DKC . Clinical survey of heart transplantation between ABO blood group-incompatible recipients and donors. J Heart Transplant 1990;9:376-381
Medline14
Fong SW ,Qaqundah BY ,Taylor WF . Developmental patterns of ABO isoagglutinins in normal children correlated with the effects of age, sex, and maternal isoagglutinins. Transfusion 1974;14:551-559
CrossRef | Web of Science | Medline15
Ferriani VP ,Barbosa JE ,de Carvalho IF . Serum haemolytic classical and alternative pathways of complement in infancy: age-related changes. Acta Paediatr Scand 1990;79:322-327
CrossRef | Web of Science | Medline16
Boucek MM ,Faro A ,Novick RJ , et al. The Registry of the International Society of Heart and Lung Transplantation: third official pediatric report-1999. J Heart Lung Transplant 1999;18:1151-1172
CrossRef | Web of Science | Medline17
Morrow WR ,Naftel D ,Chinnock R , et al. Outcome of listing for heart transplantation in infants younger than six months: predictors of death and interval to transplantation. J Heart Lung Transplant 1997;16:1255-1266
Web of Science | Medline18
Becker BN . Mycophenolate mofetil. Transplant Proc 1999;31:2777-2778
CrossRef | Web of Science | Medline19
Seebacher G ,Weigel G ,Griesmacher A , et al. One and a half years of experience with mycophenolate mofetil (Cellcept) in cardiac transplantation: a prospective, randomized study. Transplant Proc 1999;31:3291-3293
CrossRef | Web of Science | Medline20
Billingham ME ,Cary NR ,Hammond ME , et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection. J Heart Transplant 1990;9:587-593
Medline21
Fredrich R ,Toyoda M ,Czer LS , et al. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation 1999;67:385-391
CrossRef | Web of Science | Medline22
Larson DF ,Copeland JG ,Russell DH . Catecholamine-induced cardiac hypertrophy in a denervated, hemodynamically non-stressed heart transplant. Life Sci 1985;36:2477-2489
CrossRef | Web of Science | Medline23
Werner JC ,Sicard RE ,Hansen TW ,Solomon E ,Cowett RM ,Oh W . Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia. J Pediatr 1992;120:286-291
CrossRef | Web of Science | Medline24
Atkison P ,Joubert G ,Barron A , et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995;345:894-896
CrossRef | Web of Science | Medline25
Bailey LL ,Gundry SR ,Razzouk AJ ,Wang N ,Sciolaro CM ,Chiavarelli M . Bless the babies: one hundred fifteen late survivors of heart transplantation during the first year of life. J Thorac Cardiovasc Surg 1993;105:805-815
Web of Science | Medline26
Dapper F ,Bauer J ,Kroll J , et al. Clinical experience with heart transplantation in infants. Eur J Cardiothorac Surg 1998;14:1-5
CrossRef | Web of Science | Medline27
Cadoz M . Potential and limitations of polysaccharide vaccines in infancy. Vaccine 1998;16:1391-1395
CrossRef | Web of Science | Medline28
Ahmad H ,Chapnick EK . Conjugated polysaccharide vaccines. Infect Dis Clin North Am 1999;13:113-133
CrossRef | Web of Science | Medline29
Springer GF ,Horton RE . Blood group isoantibody stimulation in man by feeding blood group-active bacteria. J Clin Invest 1969;48:1280-1291
CrossRef | Web of Science | Medline30
Yandza T ,Lambert T ,Alvarez F , et al. Outcome of ABO-incompatible liver transplantation in children with no specific alloantibodies at the time of transplantation. Transplantation 1994;58:46-50
Web of Science | Medline31
Rieben R ,Korchagina EY ,von Allmen E , et al. In vitro evaluation of the efficacy and biocompatibility of new, synthetic ABO immunoabsorbents. Transplantation 1995;60:425-430
CrossRef | Web of Science | Medline32
Cooper DKC ,Ye Y ,Miekrasz M , et al. Specific intravenous carbohydrate therapy: a new concept in inhibiting antibody-mediated rejection -- experience with ABO-incompatible cardiac allografting in the baboon. Transplantation 1993;56:769-777
CrossRef | Web of Science | Medline33
Thompson JS ,Thacker LR II ,Takemoto S . The influence of conventional and cross-reactive group HLA matching on cardiac transplant outcome: an analysis from the United Network of Organ Sharing Scientific Registry. Transplantation 2000;69:2178-2186
CrossRef | Web of Science | Medline34
Platt J . A perspective on xenograft rejection and accommodation. Immunol Rev 1994;141:127-149
CrossRef | Web of Science | Medline35
Dalmasso AP ,Platt JL . Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor. Transplantation 1993;56:1171-1176
CrossRef | Web of Science | Medline36
Bach FH ,Ferran C ,Hechenleitner P , et al. Accommodation of vascularized xenografts: expression of “protective genes“ by donor endothelial cells in a host Th2 cytokine environment. Nat Med 1997;3:196-204
CrossRef | Web of Science | Medline37
Rieben R ,Tucci A ,Nydegger UE ,Zubler RH . Self tolerance to human A and B histo-blood group antigens exists at the B cell level and cannot be broken by potent polyclonal B cell activation in vitro. Eur J Immunol 1992;22:2713-2717
CrossRef | Web of Science | Medline38
Klinman NR . The “clonal selection hypothesis“ and current concepts of B cell tolerance. Immunity 1996;5:189-195
CrossRef | Web of Science | Medline39
Dintzis RZ ,Middleton MH ,Dintzis HM . Studies on the immunogenicity and tolerogenicity of T-independent antigens. J Immunol 1983;131:2196-2203
Web of Science | Medline
- Citing Articles (122)
Citing Articles
1
Rebecca Ameduri, Charles E. Canter. 2012. Pediatric Heart Transplantation. , 1001-1020.
CrossRef2
Stephen A. Stayer, Glynn Williams, Dean B. Andropoulos. 2012. Anesthesia for Transplantation. , 678-719.
CrossRef3
Heather T. Henderson, Charles E. Canter, William T. Mahle, Anne I. Dipchand, Kelci LaPorte, Kenneth B. Schechtman, Jie Zheng, Alfred Asante-Korang, Rakesh K. Singh, Kirk R. Kanter. (2012) ABO-incompatible heart transplantation: Analysis of the Pediatric Heart Transplant Study (PHTS) database. The Journal of Heart and Lung Transplantation 31:2, 173-179
CrossRef4
Kurt R. Schumacher, Robert J. Gajarski, Simon Urschel. (2012) Pediatric Coronary Allograft Vasculopathy-A Review of Pathogenesis and Risk Factors. Congenital Heart Diseaseno-no
CrossRef5
Jeffrey A. Feinstein, D. Woodrow Benson, Anne M. Dubin, Meryl S. Cohen, Dawn M. Maxey, William T. Mahle, Elfriede Pahl, Juan Villafañe, Ami B. Bhatt, Lynn F. Peng, Beth Ann Johnson, Alison L. Marsden, Curt J. Daniels, Nancy A. Rudd, Christopher A. Caldarone, Kathleen A. Mussatto, David L. Morales, D. Dunbar Ivy, J. William Gaynor, James S. Tweddell, Barbara J. Deal, Anke K. Furck, Geoffrey L. Rosenthal, Richard G. Ohye, Nancy S. Ghanayem, John P. Cheatham, Wayne Tworetzky, Gerard R. Martin. (2012) Hypoplastic Left Heart Syndrome. Journal of the American College of Cardiology 59:1, S1-S42
CrossRef6
J. Conway, C. Manlhiot, T. Allain-Rooney, B. W. McCrindle, W. Lau, A. I. Dipchand. (2012) Development of Donor-Specific Isohemagglutinins Following Pediatric ABO-Incompatible Heart Transplantation. American Journal of Transplantationno-no
CrossRef7
M. Jeyakanthan, L. J. West. (2012) Donor-Specific Isohemagglutinins: Measuring the Unknown. American Journal of Transplantationno-no
CrossRef8
Lori J. West. (2011) Antibodies and ABO-incompatibility in pediatric transplantation. Pediatric Transplantation 15:8, 778-783
CrossRef9
H. Grasemann, M. de Perrot, G. N. Bendiak, P. Cox, G. S. van Arsdell, S. Keshavjee, M. Solomon. (2011) ABO-Incompatible Lung Transplantation in an Infant. American Journal of Transplantationno-no
CrossRef10
Thomas Gelas, Patrick J. McKiernan, Deirdre A. Kelly, David A. Mayer, Darius F. Mirza, Khalid Sharif. (2011) ABO-incompatible pediatric liver transplantation in very small recipients: Birmingham’s experience. Pediatric Transplantation 15:7, 706-711
CrossRef11
Jean Kwun, Pinar Bulut, Eugenia Kim, Wasim Dar, Byoungchol Oh, Ravi Ruhil, Neal Iwakoshi, Stuart J. Knechtle. (2011) The role of B cells in solid organ transplantation. Seminars in Immunology
CrossRef12
Dirk J. van der Windt, Eefje M. Dons, Claudia L. Montoya, Mohamed Ezzelarab, Cassandra Long, Roman F. Wolf, Jan N. M. IJzermans, Fadi G. Lakkis, David K. C. Cooper. (2011) T-lymphocyte homeostasis and function in infant baboons: implications for transplantation. Transplant Internationalno-no
CrossRef13
Lori J. West. (2011) ABO-incompatible hearts for infant transplantation. Current Opinion in Organ Transplantation 16:5, 548-554
CrossRef14
Brian Feingold, Jay S. Raval, Csaba Galambos, Mark Yazer, Adriana Zeevi, Carol Bentlejewski, Victor O. Morell, Peter D. Wearden, Steven A. Webber. (2011) Tolerance to incompatible ABO blood group antigens is not observed following homograft implantation. Human Immunology 72:10, 835-840
CrossRef15
Robert A. Montgomery, Emanuele Cozzi, Lori J. West, Daniel S. Warren. (2011) Humoral immunity and antibody-mediated rejection in solid organ transplantation. Seminars in Immunology 23:4, 224-234
CrossRef16
Jeffrey L. Platt. (2011) A Symposium on Donor-Specific Antibodies after Transplantation Introduction. Pediatric Transplantation 15:5, 455-457
CrossRef17
Gunnar Tydén, Gunilla Kumlien, Ulla B. Berg. (2011) ABO-incompatible kidney transplantation in children. Pediatric Transplantation 15:5, 502-504
CrossRef18
T. P. Singh, C. S. Almond, G. Piercey, K. Gauvreau. (2011) Trends in Wait-List Mortality in Children Listed for Heart Transplantation in the United States: Era Effect Across Racial/Ethnic Groups. American Journal of Transplantationno-no
CrossRef19
Maria Herthelius, Gianni Celsi, Stella Edström Halling, Rafael T. Krmar, John Sandberg, Gunnar Tydén, Kajsa Åsling-Monemi, Ulla B. Berg. (2011) Renal transplantation in infants and small children. Pediatric Nephrology
CrossRef20
OP Yadava. (2011) Cardiac transplantation in India: Indications and eligibility. Indian Journal of Transplantation 5:3, 134-147
CrossRef21
Annette Y. Schure, Barry D. Kussman. (2011) Pediatric heart transplantation: demographics, outcomes, and anesthetic implications*. Pediatric Anesthesia 21:5, 594-603
CrossRef22
Kathryn J. Wood, Andrew Bushell, Nick D. Jones. (2011) Immunologic unresponsiveness to alloantigen in vivo: a role for regulatory T cells. Immunological Reviews 241:1, 119-132
CrossRef23
Claire A. Irving, Richard Kirk, Gareth Parry, Leslie Hamilton, John H. Dark, Neil Wrightson, Massimo Griselli, Asif Hasan. (2011) Outcomes following more than two decades of paediatric cardiac transplantation. European Journal of Cardio-Thoracic Surgery
CrossRef24
Rupali Gandhi, Christopher Almond, Tajinder P. Singh, Kimberlee Gauvreau, Gary Piercey, Ravi R. Thiagarajan. (2011) Factors associated with in-hospital mortality in infants undergoing heart transplantation in the United States. The Journal of Thoracic and Cardiovascular Surgery 141:2, 531-536.e1
CrossRef25
James A. DiNardo, Avinash C. Shukla, Francis X. McGowan. 2011. Anesthesia for Congenital Heart Surgery. , 605-673.
CrossRef26
Steven R. Sloan. (2011) Neonatal transfusion review. Pediatric Anesthesia 21:1, 25-30
CrossRef27
Peter J. Meloncelli, Todd L. Lowary. (2010) Synthesis of ABO histo-blood group type I and II antigens. Carbohydrate Research 345:16, 2305-2322
CrossRef28
Goutham Kumar, Burcin Ekser, Kareem M. Abu-Elmagd, David K.C. Cooper. (2010) Multivisceral xenotransplantation-does it have a future?. Xenotransplantation 17:6, 418-422
CrossRef29
Allan D. Kirk, Nicole A. Turgeon, Neal N. Iwakoshi. (2010) B cells and transplantation tolerance. Nature Reviews Nephrology 6:10, 584-593
CrossRef30
Elfriede Pahl, Anne I. Dipchand, Michael Burch. (2010) Heart Transplantation for Heart Failure in Children. Heart Failure Clinics 6:4, 575-589
CrossRef31
Maria Rosa Costanzo, Maria Rosa Costanzo, Anne Dipchand, Randall Starling, Allen Anderson, Michael Chan, Shashank Desai, Savitri Fedson, Patrick Fisher, Gonzalo Gonzales-Stawinski, Luigi Martinelli, David McGiffin, Francesco Parisi, Jon Smith, David Taylor, Bruno Meiser, Steven Webber, David Baran, Michael Carboni, Thomas Dengler, David Feldman, Maria Frigerio, Abdallah Kfoury, Daniel Kim, Jon Kobashigawa, Michael Shullo, Josef Stehlik, Jeffrey Teuteberg, Patricia Uber, Andreas Zuckermann, Sharon Hunt, Michael Burch, Geetha Bhat, Charles Canter, Richard Chinnock, Marisa Crespo-Leiro, Reynolds Delgado, Fabienne Dobbels, Kathleen Grady, Kao W, Jaqueline Lamour, Gareth Parry, Jignesh Patel, Daniela Pini, Sean Pinney, Jeffrey Towbin, Gene Wolfel, Diego Delgado, Howard Eisen, Lee Goldberg, Jeff Hosenpud, Maryl Johnson, Anne Keogh, Clive Lewis, John O'Connell, Joseph Rogers, Heather Ross, Stuart Russell, Johan Vanhaecke. (2010) The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. The Journal of Heart and Lung Transplantation 29:8, 914-956
CrossRef32
David K.C. Cooper, Jeffrey J. Teuteberg. (2010) Pig heart xenotransplantation as a bridge to allotransplantation. The Journal of Heart and Lung Transplantation 29:8, 838-840
CrossRef33
Xiaohu Fan, Haili Lang, Xianpei Zhou, Li Zhang, Rong Yin, Jessica Maciejko, Vasiliki Giannitsos, Bruce Motyka, Jeffrey A. Medin, Jeffrey L. Platt, Lori J. West. (2010) Induction of Human Blood Group A Antigen Expression on Mouse Cells, Using Lentiviral Gene Transduction. Human Gene Therapy 21:7, 877-890
CrossRef34
S O Kyosen, S Iizuka, H Kobayashi, T Kimura, T Fukuda, J Shen, Y Shimada, H Ida, Y Eto, T Ohashi. (2010) Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction. Gene Therapy 17:4, 521-530
CrossRef35
M. R. Johnson, K. H. Meyer, J. Haft, D. Kinder, S. A. Webber, D. B. Dyke. (2010) Heart Transplantation in the United States, 1999-2008. American Journal of Transplantation 10:4p2, 1035-1046
CrossRef36
Jennifer Conway, Anne I. Dipchand. (2010) Heart Transplantation in Children. Pediatric Clinics of North America 57:2, 353-373
CrossRef37
Burcin Ekser, David KC Cooper. (2010) Overcoming the barriers to xenotransplantation: prospects for the future. Expert Review of Clinical Immunology 6:2, 219-230
CrossRef38
A. I. Dipchand, S. M. Pollock BarZiv, C. Manlhiot, L. J. West, M. VanderVliet, B. W. McCrindle. (2010) Equivalent Outcomes for Pediatric Heart Transplantation Recipients: ABO-Blood Group Incompatible versus ABO-Compatible. American Journal of Transplantation 10:2, 389-397
CrossRef39
S. Urschel, P. M. Campbell, S. R. Meyer, I. M. Larsen, J. Nuebel, J. Birnbaum, H. Netz, K. Tinckam, T. Kauke, K. Derkatz, J. Y. Coe, J. L. Platt, L. J. West. (2010) Absence of Donor-Specific Anti-HLA Antibodies After ABO-Incompatible Heart Transplantation in Infancy: Altered Immunity or Age?. American Journal of Transplantation 10:1, 149-156
CrossRef40
Zbigniew M. Szczepiorkowski, Jeffrey L. Winters, Nicholas Bandarenko, Haewon C. Kim, Michael L. Linenberger, Marisa B. Marques, Ravindra Sarode, Joseph Schwartz, Robert Weinstein, Beth H. Shaz. (2010) Guidelines on the use of therapeutic apheresis in clinical practice-Evidence-based approach from the apheresis applications committee of the American Society for Apheresis. Journal of Clinical Apheresis 25:3, 83-177
CrossRef41
Anne I. Dipchand, Elizabeth D. Blume. 2010. Transplantation of the Heart, and Heart and Lungs. , 269-289.
CrossRef42
Leonard L. Bailey. (2009) The Evolution of Infant Heart Transplantation. The Journal of Heart and Lung Transplantation 28:12, 1241-1245
CrossRef43
Melanie D. Everitt, Amy E. Donaldson, T. Charles Casper, Josef Stehlik, John A. Hawkins, Lloyd Y. Tani, Dale G. Renlund, Peter C. Kouretas, Aditya K. Kaza, Emily A. Bullock, Michelle Cardon, Abdallah G. Kfoury. (2009) Effect of ABO-Incompatible Listing on Infant Heart Transplant Waitlist Outcomes: Analysis of the United Network for Organ Sharing (UNOS) Database. The Journal of Heart and Lung Transplantation 28:12, 1254-1260
CrossRef44
SUE PONDROM. (2009) The AJT Report: News and issues that affect organ and tissue transplantation. American Journal of Transplantation 9:12, 2649-2650
CrossRef45
Lori J. West. (2009) Lost in Regulation: Why Do U.S. Policies for ABO-incompatible Transplantation for Infants Lag Behind?. The Journal of Heart and Lung Transplantation 28:12, 1246-1248
CrossRef46
Richard Kirk, David Naftel, Timothy M. Hoffman, Christopher Almond, Gerard Boyle, Randall L. Caldwell, James K. Kirklin, Kirstie White, Anne I. Dipchand. (2009) Outcome of Pediatric Patients With Dilated Cardiomyopathy Listed for Transplant: A Multi-institutional Study. The Journal of Heart and Lung Transplantation 28:12, 1322-1328
CrossRef47
Jeffrey L. Platt, Marilia Cascalho, Lori West. (2009) Lessons from cardiac transplantation in infancy. Pediatric Transplantation 13:7, 814-819
CrossRef48
S. Urschel, R. Dalla Pozza, M. Loeff, C. Schmitz, R. Sodian, M. Schmoeckel, C. Kowalski, H. Netz. (2009) Successful ABO-incompatible heart transplantation in a child despite blood-group sensitization after ventricular assist device support. Pediatric Transplantation 13:6, 773-776
CrossRef49
David J Barron, Mark D Kilby, Ben Davies, John GC Wright, Timothy J Jones, William J Brawn. (2009) Hypoplastic left heart syndrome. The Lancet 374:9689, 551-564
CrossRef50
Zoe A. Stewart, Jayme E. Locke, Robert A. Montgomery, Andrew L. Singer, Andrew M. Cameron, Dorry L. Segev. (2009) ABO-incompatible deceased donor liver transplantation in the United States: A national registry analysis. Liver Transplantation 15:8, 883-893
CrossRef51
Winston Bharat, Cedric Manlhiot, Brian W. McCrindle, Stacey Pollock-BarZiv, Anne I. Dipchand. (2009) The profile of renal function over time in a cohort of pediatric heart transplant recipients. Pediatric Transplantation 13:1, 111-118
CrossRef52
W. Robert Morrow. (2009) Outcomes following heart transplantation in children. Progress in Pediatric Cardiology 26:1, 39-46
CrossRef53
Brian Feingold, Peter D. Wearden, Victor O. Morell, Daniel Galvis, Csaba Galambos. (2009) Expression of A and B Blood Group Antigens on Cryopreserved Homografts. The Annals of Thoracic Surgery 87:1, 211-214
CrossRef54
Paul W.M. Fedak. (2008) Cardiac Regeneration with Embryonic Stem Cells: Historic Recapitulation of Heart Transplantation. Stem Cells and Development 17:6, 1021-1022
CrossRef55
Beth D. Kaufman, Robert E. Shaddy, Girish S. Shirali, Ronn Tanel, Jeffrey A. Towbin. (2008) Assessment and management of the failing heart in children. Cardiology in the Young 18:S3, 63
CrossRef56
Yasin Aliç, Elif A. Akpek, Asl Dönmez, Süleyman Özkan, Güray Yener Perfusionist, Sait Aşlamaci. (2008) ABO-Incompatible Blood Transfusion and Invasive Therapeutic Approaches During Pediatric Cardiopulmonary Bypass. Anesthesia & Analgesia 107:4, 1185-1187
CrossRef57
Nishant D. Patel, Eric S. Weiss, Janet Scheel, Duke E. Cameron, Luca A. Vricella. (2008) ABO-Incompatible Heart Transplantation in Infants: Analysis of the United Network for Organ Sharing Database. The Journal of Heart and Lung Transplantation 27:10, 1085-1089
CrossRef58
Samuel J. Balin, Jeffrey L. Platt, Marilia Cascalho. (2008) New insights into the functions of B cells. Pediatric Transplantation 12:5, 510-515
CrossRef59
Antonio Gambino, Gianluca Torregrossa, Emanuele Cozzi, Annalisa Angelini, Giustina De Silvestro, Alessia Cerutti, Giuseppe Feltrin, Giuseppe Toscano, Chiara dʼAgostino, Fabio Zanella, Gaetano Thiene, Gino Gerosa. (2008) ABO-incompatible heart transplantation: crossing the immunological barrier. Journal of Cardiovascular Medicine 9:8, 854-857
CrossRef60
Sharon A. Hunt, François Haddad. (2008) The Changing Face of Heart Transplantation. Journal of the American College of Cardiology 52:8, 587-598
CrossRef61
J. C. Magee, S. M. Krishnan, M. R. Benfield, D. T. Hsu, B. L. Shneider. (2008) Pediatric Transplantation in the United States, 1997–2006. American Journal of Transplantation 8:4p2, 935-945
CrossRef62
Hiroto Egawa, Hideki Ohdan, Hironori Haga, Tatsuaki Tsuruyama, Fumitaka Oike, Shinji Uemoto, Kazue Ozawa. (2008) Current status of liver transplantation across ABO blood-type barrier. Journal of Hepato-Biliary-Pancreatic Surgery 15:2, 131-138
CrossRef63
Sharon M. Bartosh, Frederick C. Ryckman, Robert Shaddy, Marian G. Michaels, Jeffrey L. Platt, Stuart C. Sweet. (2008) A national conference to determine research priorities in pediatric solid organ transplantation. Pediatric Transplantation 12:2, 153-166
CrossRef64
S. M. Pollock-BarZiv, B. W. McCrindle, L. J. West, A. I. Dipchand. (2008) Waiting Before Birth: Outcomes After Fetal Listing for Heart Transplantation. American Journal of Transplantation 8:2, 412-418
CrossRef65
T. Irei, H. Ohdan, W. Zhou, K. Ishiyama, Y. Tanaka, K. Ide, T. Asahara. (2007) The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade: novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation. Blood 110:13, 4567-4575
CrossRef66
Pleunie P. M. Rood, Hao-Chih Tai, Hidetaka Hara, Cassandra Long, Mohamed Ezzelarab, Yih J. Lin, Dirk J. van der Windt, Jamie Busch, David Ayares, Jan N. M. Ijzermans, Roman F. Wolf, Rizwan Manji, Leonard Bailey, David K. C. Cooper. (2007) Late onset of development of natural anti-nonGal antibodies in infant humans and baboons: implications for xenotransplantation in infants. Transplant International 20:12, 1050-1058
CrossRef67
S. L. Roche, M. Burch, J. O'Sullivan, J. Wallis, G. Parry, R. Kirk, M. Elliot, N. Shaw, J. Flett, J. R. L. Hamilton, A. Hasan. (2007) Multicenter Experience of ABO-Incompatible Pediatric Cardiac Transplantation. American Journal of Transplantation 0:0, 071117175452003-???
CrossRef68
Stacey M. Pollock-BarZiv, Brian W. McCrindle, Lori J. West, Cedric Manlhiot, Meghan VanderVliet, Anne I. Dipchand. (2007) Competing Outcomes After Neonatal and Infant Wait-listing for Heart Transplantation. The Journal of Heart and Lung Transplantation 26:10, 980-985
CrossRef69
H. Ohdan, W. Zhou, Y. Tanaka, T. Irei, Y. Fuchimoto, H. Egawa, T. Asahara. (2007) Evidence of Immune Tolerance to Blood Group Antigens in a Case of ABO-Incompatible Pediatric Liver Transplantation. American Journal of Transplantation 7:9, 2190-2194
CrossRef70
Zbigniew M. Szczepiorkowski, Nicholas Bandarenko, Haewon C. Kim, Michael L. Linenberger, Marisa B. Marques, Ravindra Sarode, Joseph Schwartz, Beth H. Shaz, Robert Weinstein, Ashka Wirk, Jeffrey L. Winters. (2007) Guidelines on the use of therapeutic apheresis in clinical practice—Evidence-based approach from the apheresis applications committee of the American society for apheresis. Journal of Clinical Apheresis 22:3, 106-175
CrossRef71
A. D. Kirk, W. M. Baldwin, M. I. Cascalho, A. S. Chong, M. Sykes, L. J. West. (2007) American Society of Transplantation Symposium on B Cells in Transplantation: Harnessing Humoral Immunity from Rodent Models to Clinical Practice. American Journal of Transplantation 7:6, 1464-1470
CrossRef72
S. Horslen, M. L. Barr, L. L. Christensen, R. Ettenger, J. C. Magee. (2007) Pediatric Transplantation in the United States, 1996?2005. American Journal of Transplantation 7:s1, 1339-1358
CrossRef73
Martin H. Bluth, Marion E. Reid, Noga Manny. (2007) Chimerism in the Immunohematology Laboratory in the Molecular Biology Era. Transfusion Medicine Reviews 21:2, 134-146
CrossRef74
Ornella Milanesi, Alessia Cerutti, Roberta Biffanti, Sabrina Salvadori, Antonio Gambino, Giovanni Stellin. (2007) Heart transplantation in pediatric age. Journal of Cardiovascular Medicine 8:1, 67-71
CrossRef75
Nadya Nalli, Lilian Stewart-Teixeira, Anne I. Dipchand. (2006) Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart transplant patient. Pediatric Transplantation 10:6, 736-739
CrossRef76
Georg Stussi, Lori West, David K. C. Cooper, Jörg D. Seebach. (2006) ABO-incompatible allotransplantation as a basis for clinical xenotransplantation. Xenotransplantation 13:5, 390-399
CrossRef77
Kristine J. Guleserian, Laurie B. Armsby, Ravi R. Thiagarajan, Pedro J. del Nido, John E. Mayer. (2006) Natural History of Pulmonary Atresia With Intact Ventricular Septum and Right-Ventricle–Dependent Coronary Circulation Managed by the Single-Ventricle Approach. The Annals of Thoracic Surgery 81:6, 2250-2258
CrossRef78
Dragan Bucin, Sune Johansson, Torsten Malm, Peeter Jogi, Jens Johansson, Per Westrin, Lars O Lindberg, Ann-Kristin Olsson, Jan Gelberg, Valeria Peres, Solweig Harling, Rolf Bennhagen, Bjorn Kornhall, Bjorn Ekmehag, Jan Kurkus, Gisela Otto. (2006) Heart transplantation across the antibodies against HLA and ABO. Transplant International 19:3, 239-244
CrossRef79
Phil Botha, Asif Hasan, Simon Haynes, Jane Cassidy, Joe Roe, John Wallis, Jon Smith. (2006) Exchange Transfusion During Extra Corporeal Membrane Oxygenation Used as a Bridge to ABO-Mismatch Cardiac Transplantation. The Annals of Thoracic Surgery 81:3, 1105-1107
CrossRef80
M ROSE. (2006) Transplant immunology I: immunological mechanisms of graft injury. Surgery (Oxford) 24:2, 47-52
CrossRef81
Lori J. West. (2006) B-cell Tolerance following ABO-Incompatible Infant Heart Transplantation. Transplantation 81:3, 301-307
CrossRef82
Lori J. West, Tara Karamlou, Anne I. Dipchand, Stacey M. Pollock-BarZiv, John G. Coles, Brian W. McCrindle. (2006) Impact on outcomes after listing and transplantation, of a strategy to accept ABO blood group-incompatible donor hearts for neonates and infants. The Journal of Thoracic and Cardiovascular Surgery 131:2, 455-461
CrossRef83
Helen Ferry, Janson C. H. Leung, Graham Lewis, Anastasia Nijnik, Karlee Silver, Teresa Lambe, Richard J. Cornall. (2006) B-cell Tolerance. Transplantation 81:3, 308-315
CrossRef84
Abdulaziz Al-khaldi, Robert C. Robbins. (2006) New Directions in Cardiac Transplantation. Annual Review of Medicine 57:1, 455-471
CrossRef85
Lori J West. (2005) ABO-incompatible heart transplantation: an alternative to improve the donor shortage in infants. Current Opinion in Organ Transplantation 10:4, 364-368
CrossRef86
Michael Schmoeckel, Sabine H. Dabritz, Rainer Kozlik-Feldmann, Georg Wittmann, Frank Christ, Christian Kowalski, Bruno M. Meiser, Heinrich Netz, Bruno Reichart. (2005) Successful ABO-incompatible heart transplantation in two infants. Transplant International 18:10, 1210-1214
CrossRef87
Robert B. Colvin, R. Neal Smith. (2005) Antibody-mediated organ-allograft rejection. Nature Reviews Immunology 5:10, 807-817
CrossRef88
Philip D Bardwell, Hideki Ohdan, Megan Sykes. (2005) B cell tolerance and xenotransplantation. Current Opinion in Organ Transplantation 10:3, 252-258
CrossRef89
G. Stussi, K. Huggel, H. U. Lutz, U. Schanz, R. Rieben, J. D. Seebach. (2005) Isotype-specific detection of ABO blood group antibodies using a novel flow cytometric method. British Journal of Haematology 130:6, 954-963
CrossRef90
Zuhaib Ibrahim, Mohamed Ezzelarab, Robert Kormos, David K. C. Cooper. (2005) Which patients first? Planning the first clinical trial of xenotransplantation: a case for cardiac bridging.. Xenotransplantation 12:3, 168-172
CrossRef91
PD Griffiths. (2005) Induced tolerance to isohaemagglutinins. Reviews in Medical Virology 15:3, 145-147
CrossRef92
Robert E. Shaddy, Thomas C. Fuller. (2005) The sensitized pediatric heart transplant candidate: Causes, consequences, and treatment options. Pediatric Transplantation 9:2, 208-214
CrossRef93
Kathryn J. Wood. (2005) Is B Cell Tolerance Essential for Transplantation Tolerance?. Transplantation 79:Supplement, S40-S42
CrossRef94
Milind Chaudhari, Jon Sturman, John O'Sullivan, Jon Smith, Neil Wrightson, Gareth Parry, David Bolton, Simon Haynes, Leslie Hamilton, Asif Hasan. (2005) Rescue cardiac transplantation for early failure of the Fontan-type circulation in children. The Journal of Thoracic and Cardiovascular Surgery 129:2, 416-422
CrossRef95
Marilia Cascalho, Jeffrey L. Platt. (2005) Basic mechanisms of humoral rejection. Pediatric Transplantation 9:1, 9-16
CrossRef96
Cynthia S. Herrington, Anna E. Tsirka. (2004) Pediatric cardiac transplantation. Seminars in Thoracic and Cardiovascular Surgery 16:4, 404-409
CrossRef97
Xiaohu Fan, Andrew Ang, Stacey M Pollock-BarZiv, Anne I Dipchand, Phillip Ruiz, Gregory Wilson, Jeffrey L Platt, Lori J West. (2004) Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nature Medicine 10:11, 1227-1233
CrossRef98
Jeffrey P. Jacobs, James A. Quintessenza, Robert J. Boucek, Victor O. Morell, Luis M. Botero, Vinay Badhwar, Hugh M. van Gelder, Alfred Asante-Korang, Jorge McCormack, George R. Daicoff. (2004) Pediatric Cardiac Transplantation in Children With High Panel Reactive Antibody. The Annals of Thoracic Surgery 78:5, 1703-1709
CrossRef99
Jagdeep S Obhrai, Fadi G Lakkis. (2004) Transplantation tolerance: babies take the first step. Nature Medicine 10:11, 1165-1166
CrossRef100
Uri Galili. (2004) Immune Response, Accommodation, and Tolerance to Transplantation Carbohydrate Antigens. Transplantation 78:8, 1093-1098
CrossRef101
Britt Hofmann, Kesheng Tao, Lydia Mai, Lori J. West. (2004) Acceptance of related and unrelated cardiac allografts in neonatally tolerized mice is cardio-specific and transferable by regulatory CD4+ T cells. The Journal of Heart and Lung Transplantation 23:9, 1069-1076
CrossRef102
Kota Takahashi, Kazuhide Saito, Shiro Takahara, Akihiko Okuyama, Kazunari Tanabe, Hiroshi Toma, Kazuharu Uchida, Akira Hasegawa, Norio Yoshimura, Yoriaki Kamiryo, . (2004) Excellent Long-term Outcome of ABO-Incompatible Living Donor Kidney Transplantation in Japan. American Journal of Transplantation 4:7, 1089-1096
CrossRef103
Nicholas R. Banner, Marlene L. Rose, David Cummins, Mahes de Silva, Alison Pottle, Haifa Lyster, Peter Doyle, Martin Carby, Asghar Khaghani. (2004) Management of an ABO-Incompatible Lung Transplant. American Journal of Transplantation 4:7, 1192-1196
CrossRef104
Jagan N. Rao, Asif Hasan, John R. L. Hamilton, David Bolton, Simon Haynes, Johnathan H. Smith, Jonathan Wallis, Patrick Kesteven, Kamran Khattak, John O???Sullivan, John H. Dark. (2004) ABO-INCOMPATIBLE HEART TRANSPLANTATION IN INFANTS: THE FREEMAN HOSPITAL EXPERIENCE. Transplantation 77:9, 1389-1394
CrossRef105
Nana Rezai, Thomas J. Podor, Bruce M. McManus. (2004) Bone Marrow Cells in the Repair and Modulation of Heart and Blood Vessels: Emerging Opportunities in Native and Engineered Tissue and Biomechanical Materials. Artificial Organs 28:2, 142-151
CrossRef106
James A. Quintessenza, Victor O. Morell, Jeffrey P. Jacobs. (2004) Achieving a balance in the current approach to the surgical treatment of hypoplastic left heart syndrome. Cardiology in the Young 14:S1, 127
CrossRef107
Robert J. Boucek, Maryanne R. K. Chrisant. (2004) Cardiac transplantation for hypoplastic left heart syndrome. Cardiology in the Young 14:S1, 83
CrossRef108
Haruko Ogawa, Muhammad M. Mohiuddin, Deng-Ping Yin, Jikun Shen, Anita S. Chong, Uri Galili. (2004) Mouse-heart grafts expressing an incompatible carbohydrate antigen. II. Transition from accommodation to tolerance. Transplantation 77:3, 366-373
CrossRef109
Hiroto Egawa, Fumitaka Oike, Leo Buhler, A. M. James Shapiro, Sachiko Minamiguchi, Hironori Haga, Kenji Uryuhara, Tetsuya Kiuchi, Satoshi Kaihara, Koichi Tanaka. (2004) Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation. Transplantation 77:3, 403-411
CrossRef110
Anne-Marie McMahon, Carin van Doorn, Michael Burch, Pauline Whitmore, Sophie Neligan, Philip Rees, Rosemary Radley-Smith, Allan Goldman, Katherine Brown, Gordon Cohen, Victor Tsang, Martin Elliott, Marc R de Leval. (2003) Improved early outcome for end-stage dilated cardiomyopathy in children. The Journal of Thoracic and Cardiovascular Surgery 126:6, 1781-1787
CrossRef111
Attapong Vongwiwatana, Adis Tasanarong, Luis G. Hidalgo, Philip F. Halloran. (2003) The role of B cells and alloantibody in the host response to human organ allografts. Immunological Reviews 196:1, 197-218
CrossRef112
(2003) Heart Failure. New England Journal of Medicine 349:10, 1002-1004
Full Text113
Anette Wu, Leo H. Buhler, David K.C. Cooper. (2003) ABO-incompatible organ and bone marrow transplantation: current status. Transplant International 16:5, 291-299
CrossRef114
Paul M. Colombani, Stephen P. Dunn, William E. Harmon, John C. Magee, Sue V. McDiarmid, Thomas L. Spray. (2003) Pediatric transplantation. American Journal of Transplantation 3:s4, 53-63
CrossRef115
Robert J Gajarski, Ralph S Mosca, Richard G Ohye, Edward L Bove, Dennis C Crowley, Joseph R Custer, Frank W Moler, Alicia Valentini, Thomas J Kulik. (2003) Use of extracorporeal life support as a bridge to pediatric cardiac transplantation. The Journal of Heart and Lung Transplantation 22:1, 28-34
CrossRef116
Estela Azeka, José Antonio Franchini Ramires, Constante Valler, Edimar Alcides Bocchi. (2002) Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. Journal of the American College of Cardiology 40:11, 2034-2038
CrossRef117
Shamila Mauiyyedi, Robert B. Colvin. (2002) Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Current Opinion in Nephrology and Hypertension 11:6, 609-618
CrossRef118
Robert J. Boucek, Mark M. Boucek. (2002) Pediatric heart transplantation. Current Opinion in Pediatrics 14:5, 611-619
CrossRef119
Eric N. Mendeloff. (2002) The history of pediatric heart and lung transplantation. Pediatric Transplantation 6:4, 270-279
CrossRef120
L.J West. (2002) Developmental aspects of immunomodulation: exploiting the immature immune system for organ transplantation. Transplant Immunology 9:2-4, 149-153
CrossRef121
Jill E Ibrahim, Stuart C Sweet, Mindee Flippin, Catherine Dent, Eric Mendelhoff, Charles B Huddleston, Kathryn Trinkhaus, Charles E Canter. (2002) Rejection is reduced in thoracic organ recipients when transplanted in the first year of life. The Journal of Heart and Lung Transplantation 21:3, 311-318
CrossRef122
Boucek, Mark M., . (2001) Breaching the Barrier of ABO Incompatibility in Heart Transplantation for Infants. New England Journal of Medicine 344:11, 843-844
Full Text
